We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Sensus Healthcare, Inc. (SRTS - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Sensus Healthcare, Inc. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SRTS' full-year earnings has moved 24.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SRTS has moved about 173.7% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 11.9% on average. This means that Sensus Healthcare, Inc. is performing better than its sector in terms of year-to-date returns.
Assembly Biosciences (ASMB - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 63.4%.
The consensus estimate for Assembly Biosciences' current year EPS has increased 41.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Sensus Healthcare, Inc. belongs to the Medical - Instruments industry, a group that includes 85 individual companies and currently sits at #77 in the Zacks Industry Rank. This group has gained an average of 9.9% so far this year, so SRTS is performing better in this area.
On the other hand, Assembly Biosciences belongs to the Medical - Generic Drugs industry. This 11-stock industry is currently ranked #48. The industry has moved +20.3% year to date.
Investors with an interest in Medical stocks should continue to track Sensus Healthcare, Inc. and Assembly Biosciences. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Sensus Healthcare, Inc. (SRTS - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Sensus Healthcare, Inc. is one of 1017 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for SRTS' full-year earnings has moved 24.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SRTS has moved about 173.7% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 11.9% on average. This means that Sensus Healthcare, Inc. is performing better than its sector in terms of year-to-date returns.
Assembly Biosciences (ASMB - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 63.4%.
The consensus estimate for Assembly Biosciences' current year EPS has increased 41.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Sensus Healthcare, Inc. belongs to the Medical - Instruments industry, a group that includes 85 individual companies and currently sits at #77 in the Zacks Industry Rank. This group has gained an average of 9.9% so far this year, so SRTS is performing better in this area.
On the other hand, Assembly Biosciences belongs to the Medical - Generic Drugs industry. This 11-stock industry is currently ranked #48. The industry has moved +20.3% year to date.
Investors with an interest in Medical stocks should continue to track Sensus Healthcare, Inc. and Assembly Biosciences. These stocks will be looking to continue their solid performance.